Heart HealthLarge VA Study Reveals What GLP-1 Drugs Actually Do to Your Pancreas
GLP-1 receptor agonists like semaglutide and tirzepatide are among the most widely used drugs for obesity and type 2 diabetes, but questions about their safety — particularly regarding pancreatitis — have lingered for years. A new analysis of Veterans Affairs health data, discussed by NEJM's Raja-Elie Abdulnour, offers fresh evidence on this relationship. Pancreatitis is a serious, sometimes life-threatening inflammation of the pancreas, making this a critical safety question for the millions of adults now taking these medications. The findings, covered by NEJM clinician editorial staff, aim to clarify whether GLP-1 use meaningfully raises pancreatitis risk in real-world populations and what that means for prescribing decisions and long-term health planning.
